Aida Pharmaceuticals Acquires Majority Stake in Shanghai Qiaer Bio-Technology

Published on: 

Aida Pharmaceuticals (Hangzhou, China) has completed its acquisition of majority control of Shanghai Qiaer Bio-Technology Co., Ltd (Shanghai, China).

Aida Pharmaceuticals (Hangzhou, China) has completed its acquisition of majority control of Shanghai Qiaer Bio-Technology Co., Ltd (Shanghai, China). Qiaer Bio-Technology’s flagship drug, Rh-Apo2L, a gene drug developed to treat various forms of cancer, just completed Phase 1 clinical trials.